Toxic serum trough concentrations after administration of nebulized tobramycin

Pharmacotherapy

Volumn 23, Issue 4, 2003, Pages 543-545

  Kahler, Deborah A ^a   Schowengerdt, Kenneth O ^b   Fricker, F Jay ^b   Mansfield, Melissa ^c   Visner, Gary A ^b   Faro, Albert ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BASILIXIMAB; CEFEPIME; FLUCONAZOLE; FLUCYTOSINE; GANCICLOVIR; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; FEMALE; HUMANS; NEBULIZERS AND VAPORIZERS; TOBRAMYCIN;

EID: 0037380481     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.4.543.32122     Document Type: Article

References (10)

1. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30.
2. Rosenfeld M, Gibson R, McNamara S, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-7.
3. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Breimer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41(1):184-7.
4. LeConte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993;147(5):1279-82.
5. Elidemir O, Maciejewski SR, Oermann CM. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. Pediatr Pulmonol 2000;29:43-5.
6. Hoffman IM, Rubin BK, Iskander SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-7.
7. Goldstein I, Wallet F, Robert J, et al. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002;165:171-5.
8. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients. Crit Care Med 1998;26(1):31-9.
9. Coates AL, Allen PD, Eng M, MacNeish CF, Ho SL, Lands LC. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 2001;119:1123-30.
10. Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994;34(3):255-9.